The presence of CD8+ tumor-infiltrating lymphocytes (TILs) and interferon gamma (IFNγ) response signatures have been shown to be predictive biomarkers for ipilimumab response in mCRPC (35). The gene discussed is CD8A; the disease is neoplasm.